Dr. Thomas A. Ullman, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 154
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Js Weill Medical College, Cornell University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 197786
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Mount Sinai School of Medicine of New York University (30 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 154
- Services billed
- 366
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 142 | 66 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 19 | 19 |
| Biopsy of large bowel using a flexible endoscope | 19 | 18 |
| New patient office or other outpatient visit, 30-44 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mesalamine Other prescribers in Scarsdale, NY | 79 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Scarsdale, NY | 54 |
| Entyvio (vedolizumab) | 50 |
| Omeprazole Other prescribers in Scarsdale, NY | 39 |
| Xifaxan (rifaximin) Other prescribers in Scarsdale, NY | 27 |
| Stelara (ustekinumab) | 27 |
| Rinvoq (upadacitinib) | 26 |
| Pantoprazole Sodium Other prescribers in Scarsdale, NY | 21 |
| Budesonide Er (budesonide) Other prescribers in Scarsdale, NY | 19 |
| Mesalamine Er (mesalamine) Other prescribers in Scarsdale, NY | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 27 payments worth $28,849 in total to this clinician.
| Janssen Biotech, Inc. | $21,007 |
|---|---|
| Pfizer Inc. | $7,634 |
| AbbVie Inc. | $209 |
| Compensation for services other than consulting (speaking, faculty) | $25,365 |
|---|---|
| Travel and Lodging | $2,362 |
| Food and Beverage | $1,123 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) VELSIPITY · INFLAMMATION;PAIN | $6,990 |
| Janssen Biotech, Inc. Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,900 |
| Janssen Biotech, Inc. Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Nov 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Aug 9, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Dec 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Sep 9, 2025 | Travel and Lodging TREMFYA · Immunology · travel to PHILADELPHIA, PA · in-kind | $1,813 |
| Janssen Biotech, Inc. Apr 19, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $875 |
| Pfizer Inc. Mar 21, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to New York, NY · in-kind | $278 |
| Pfizer Inc. Jun 20, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to NEW YORK, NY · in-kind | $164 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Dec 8, 2025 | Travel and Lodging TREMFYA · Immunology · travel to FLUSHING, NY | $46.20 |
| Janssen Biotech, Inc. Dec 8, 2025 | Travel and Lodging TREMFYA · Immunology · travel to FLUSHING, NY | $16.00 |
| Janssen Biotech, Inc. Dec 8, 2025 | Travel and Lodging TREMFYA · Immunology · travel to FLUSHING, NY | $13.88 |
| Janssen Biotech, Inc. Nov 22, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $4,900 |
| Janssen Biotech, Inc. Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Janssen Biotech, Inc. Sep 9, 2025 | Travel and Lodging TREMFYA · Immunology · travel to PHILADELPHIA, PA · in-kind | $1,813 |
| Janssen Biotech, Inc. Aug 14, 2025 | Travel and Lodging TREMFYA · Immunology · travel to SPARKILL, NY | $25.20 |
| Janssen Biotech, Inc. Aug 14, 2025 | Travel and Lodging TREMFYA · Immunology · travel to SPARKILL, NY | $5.40 |
| Janssen Biotech, Inc. Aug 9, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $3,150 |
| Pfizer Inc. Jun 20, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to NEW YORK, NY · in-kind | $164 |
| Janssen Biotech, Inc. Apr 19, 2025 | Compensation for services other than consulting (speaking, faculty) STELARA; TREMFYA · Immunology | $875 |
| Pfizer Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) VELSIPITY · INFLAMMATION;PAIN | $6,990 |
| Pfizer Inc. Mar 21, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to New York, NY · in-kind | $278 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $7,029 in research payments for these studies, mostly to the institutions running them.
- M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.